相关实验视频

Updated: May 25, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

针对Aurora A,以克服头癌患者的西斯普拉丁耐药性

X Li¹, Z Wang², G G Oakley²

¹Department of Biomedical Sciences, Adams School of Dentistry, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Journal of dental research

|February 28, 2025

概括

用抑制剂准 Aurora A 激酶可以使头部和部状细胞癌 (HNSCC) 细胞对西斯普拉丁化疗重新敏感. 这种方法增强了细胞亡和DNA损伤,为克服HNSCC中西斯普拉丁耐药性提供了一个有希望的策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

西斯是一种高级头支状细胞癌 (HNSCC) 的标准治疗方法,但耐药性和毒性限制了其有效性.
极光激酶,特别是极光A,与细胞分裂有关,但它们在青抗性中的作用尚不清楚.

研究的目的:

为了研究 Aurora 激酶抑制剂的潜力,特别是针对 Aurora A,以克服 HNSCC. cisplatin 耐药性的潜力.
阐明 Aurora A 抑制影响西斯普拉丁反应和 DNA 损伤修复的机制.

主要方法:

复合查以识别潜在的敏感化剂.
在HNSCC细胞中,Aurora A及其激活剂的耗尽.
对Aura A表达和与临床结果的相关性进行患者数据库和瘤样本的分析.
在细胞和体内 (小鼠模型) HNSCC研究中对Aurora A的药理抑制.
对亡,复制应激和DNA交联修复的机制研究.

主要成果:

欧罗拉A抑制使抗性HNSCC细胞对西斯素敏感.
在HNSCC患者中,极光A的过度表达/激活与西斯普拉丁耐药性,复发和低生存率相关.
在体外和体内,药理上抑制Aurora A与西斯普拉丁协同作用.
光A抑制增强了西斯胺诱导的亡,复制压力,并抑制了DNA修复.

结论:

紫外线A激酶在HNSCC中在已知的线粒功能之外,在cisplatin耐药性中发挥着重要作用.
在HNSCC中,Aurora A是一种潜在的治疗点,可以克服cisplatin耐药性.
与Aurora A抑制剂和金药物的联合治疗显示出对HNSCC治疗的前景.

关键词:

光酶是一种激酶.修复DNA损伤的修复在HNSCC中,我们可以看到HNSCC.癌症治疗疗法癌症治疗西斯普拉丁 (cisplatin) 是一种制剂.复制压力是复制的压力.瘤的复发瘤的复发

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...